Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

NCT06936215 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Cutaneous Systemic Sclerosis

Interventions

DRUG: tab baricitinib 4 mg daily
DRUG: tab methotrexate 25 mg weekly with folic acid 5 mg weekly

Sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh